🔴 IBRX is trading 6.5% down today on profit-taking after its FDA sBLA acceptance rally

IBRX is trading at $7.53 (-6.52%) as the stock undergoes a sharp pullback following a rally sparked by the FDA’s acceptance of its supplemental BLA for ANKTIVA plus BCG.

• High trading volume indicates active investor repositioning and consolidation as momentum cools following the recent regulatory milestone.
• Broader biotech sector weakness and a softer overall market tone are adding additional downward pressure to the stock.